NOVT earnings analysis
What we found in NOVT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Novanta Inc. reported Q1 2026 results with total revenue of $257.7 million, up 10.4% year-over-year, and diluted EPS at $0.51, a decrease from the prior year's $0.59. Segment performance showed strong growth in the Medical Solutions segment, which increased by 14.8%, while Automation Enabling Technologies rose by 6.6%. Operating income decreased to $27.5 million due to higher SG&A and restructuring costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Total revenue reached $257.7 million, a 10.4% increase from the prior year.
- Medical Segment Strength
- Medical Solutions revenue increased by $16.3 million or 14.8% from last year.
- Improved EPS
- Q1 EPS of $0.51 decreased from $0.59, but was above consensus of $0.78.
- Cash Flow Increase
- Operating cash flow improved to $51.6 million from $31.7 million year-over-year.
- Debt Levels Reduced
- Net interest expense decreased to $1.8 million from $5.6 million, reflecting lower average debt.
- Strong Liquidity
- Cash and cash equivalents increased to $388.8 million from $380.9 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Costs
- Operating income fell 15.1% to $27.5 million due to increasing expenses.
- Margin Compression
- Gross margin decreased to 44.1% from 44.7% due to higher material and tariff costs.
- Geopolitical and Economic Risks
- Weakening market demand due to geopolitical tensions may adversely affect revenue.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.51
- Gross margin
- 44.1%
- Operating margin
- 10.7%
- Segment
- Automation Enabling Technologies: $131.2M
- Segment
- Medical Solutions: $126.5M
What they said about what is next.
For FY 2026, management anticipates revenue between $1.040 billion and $1.055 billion.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 23, 2026
- Novanta reports FY2025 revenue of $980.6 million (Automation Enabling Technologies $500.8M; Medical Solutions $479.8M) with backlog up to $481.2 million from $445.5 million a year earlier. The company strengthened…
- 10-Q · August 5, 2025
- Novanta reported Q2 revenue of $241.05M, up 2.2% year-over-year and 3.4% sequentially, but operating profit and EPS compressed due to elevated acquisition and restructuring costs and FX losses. Balance sheet shows…
- 10-Q · May 6, 2025
- Novanta reported Q1 revenue of $233,366,000, up $2,450,000 versus Q1 2024, with gross profit of $104,354,000 (44.7% margin) and operating income of $32,421,000 (13.9% margin). Diluted EPS was $0.59 versus $0.41 a year…
- 10-Q · November 5, 2024
- Novanta reported Q3 revenue of $244.405 million, up $22.902 million (+10.3%) versus Q3 2023, with gross profit of $109.215 million. Operating income rose to $32.555 million but diluted EPS fell to $0.53 from $0.59 a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NOVT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever